Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in Pharmacogenomics Reporter on July 31, 2011 titled “Appeals Court Decides Isolated DNA Patentable, Myriad’s Analytical Method Claims Not.” Brinckerhoff discusses the Court of Appeals for the Federal Circuit’s ruling that isolated gene sequences are patentable, stating that the decision could have a far-reaching impact on other patents and personalized medicine type claims. She adds that practitioners and patent holders may want to review pending and granted claims to determine if they are affected by recent decisions regarding gene patent eligibility.
